Solo Metadatos

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

dc.creatorMuñoz, Nubiaspa
dc.creatorKjaer, Susanne K.spa
dc.creatorSigurdsson, Kristjánspa
dc.creatorIversen, Ole-Erikspa
dc.creatorHernandez-Avila, Mauriciospa
dc.creatorWheeler, Cosette M.spa
dc.creatorPerez, Gonzalospa
dc.creatorBrown, Darron R.spa
dc.creatorKoutsky, Laura A.spa
dc.creatorTay, Eng Hseonspa
dc.creatorGarcia, Patricía J.spa
dc.creatorAult, Kevin A.spa
dc.creatorGarland, Suzanne M.spa
dc.creatorLeodolter, Seppspa
dc.creatorOlsson, Sven-Ericspa
dc.creatorTang, Grace W. K.spa
dc.creatorFerris, Daron G.spa
dc.creatorPaavonen, Jormaspa
dc.creatorSteben, Marcspa
dc.creatorBosch, F. Xavierspa
dc.creatorDillner, Joakimspa
dc.creatorHuh, Warner K.spa
dc.creatorJoura, Elmar A.spa
dc.creatorKurman, Robert J.spa
dc.creatorMajewski, Slawomirspa
dc.creatorMyers, Evan R.spa
dc.creatorVilla, Luisa L.spa
dc.creatorTaddeo, Frank J.spa
dc.creatorRoberts, Christinespa
dc.creatorTadesse, Amhaspa
dc.creatorBryan, Janine T.spa
dc.creatorLupinacci, Lisa C.spa
dc.creatorGiacoletti, Katherine E. D.spa
dc.creatorSings, Heather L.spa
dc.creatorJames, Margaret K.spa
dc.creatorHesley, Teresa M.spa
dc.creatorBarr, Eliavspa
dc.creatorHaupt, Richard M.spa
dc.description.abstractBackground The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were 'negative to 14 HPV types' and in a mixed population of HPV-exposed and-unexposed women (intention-to-treat group).MethodsThis analysis studied 17 622 women aged 15-26 years who were enrolled in one of two randomized, placebo-controlled, efficacy trials for the HPV6/11/16/18 vaccine (first patient on December 28, 2001, and studies completed July 31, 2007). Vaccine or placebo was given at day 1, month 2, and month 6. All women underwent cervicovaginal sampling and Papanicolaou (Pap) testing at day 1 and every 6-12 months thereafter. Outcomes were any cervical intraepithelial neoplasia; any external anogenital and vaginal lesions; Pap test abnormalities; and procedures such as colposcopy and definitive therapy. Absolute rates are expressed as women with endpoint per 100 person-years at risk.ResultsThe average follow-up was 3.6 years (maximum of 4.9 years). In the population that was negative to 14 HPV types, vaccination was up to 100% effective in reducing the risk of HPV16/18-related high-grade cervical, vulvar, and vaginal lesions and of HPV6/11-related genital warts. In the intention-to-treat group, vaccination also statistically significantly reduced the risk of any high-grade cervical lesions (19.0% reduction; rate vaccine = 1.43, rate placebo = 1.76, difference = 0.33, 95% confidence interval [CI] = 0.13 to 0.54), vulvar and vaginal lesions (50.7% reduction; rate vaccine = 0.10, rate placebo = 0.20, difference = 0.10, 95% CI = 0.04 to 0.16), genital warts (62.0% reduction; rate vaccine = 0.44, rate placebo = 1.17, difference = 0.72, 95% CI = 0.58 to 0.87), Pap abnormalities (11.3% reduction; rate vaccine = 10.36, rate placebo = 11.68, difference = 1.32, 95% CI = 0.74 to 1.90), and cervical definitive therapy (23.0% reduction; rate vaccine = 1.97, rate placebo = 2.56, difference = 0.59, 95% CI = 0.35 to 0.83), irrespective of causal HPV type.ConclusionsHigh-coverage HPV vaccination programs among adolescents and young women may result in a rapid reduction of genital warts, cervical cytological abnormalities, and diagnostic and therapeutic procedures. In the longer term, substantial reductions in the rates of cervical, vulvar, and vaginal cancers may follow.eng
dc.relation.citationIssueNo. 5
dc.relation.citationTitleJournal of the National Cancer Institute
dc.relation.citationVolumeVol. 102
dc.relation.ispartofJournal of the National Cancer Institute, ISSN:278874, Vol.102, No.5 (2010); pp. 325-339spa
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAluminum hydroxyphosphate sulfatespa
dc.subject.keywordImmunological adjuvantspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordWart virus vaccinespa
dc.subject.keywordAdenocarcinoma in situspa
dc.subject.keywordAdjuvant therapyspa
dc.subject.keywordCarcinoma in situspa
dc.subject.keywordClinical trialspa
dc.subject.keywordCondyloma acuminatumspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordFollow upspa
dc.subject.keywordGynecologic diseasespa
dc.subject.keywordHuman papillomavirus type 11spa
dc.subject.keywordHuman papillomavirus type 16spa
dc.subject.keywordHuman papillomavirus type 18spa
dc.subject.keywordHuman papillomavirus type 6spa
dc.subject.keywordHuman tissuespa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordPapanicolaou testspa
dc.subject.keywordPopulation exposurespa
dc.subject.keywordPriority journalspa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordRisk reductionspa
dc.subject.keywordUterine cervix carcinoma in situspa
dc.subject.keywordUterine cervix cytologyspa
dc.subject.keywordVagina cancerspa
dc.subject.keywordVagina intraepithelial neoplasiaspa
dc.subject.keywordVulva cancerspa
dc.subject.keywordVulva intraepithelial neoplasiaspa
dc.subject.keywordCervical intraepithelial neoplasiaspa
dc.subject.keywordGenital diseaseseng
dc.subject.keywordHuman papillomavirus 11spa
dc.subject.keywordHuman papillomavirus 16spa
dc.subject.keywordHuman papillomavirus 18spa
dc.subject.keywordHuman papillomavirus 6spa
dc.subject.keywordKaplan-meiers estimatespa
dc.subject.keywordPapillomavirus infectionsspa
dc.subject.keywordPapillomavirus vaccinesspa
dc.subject.keywordSexual partnersspa
dc.subject.keywordSexually transmitted diseasesspa
dc.subject.keywordTumor virus infectionsspa
dc.subject.keywordUterine cervical neoplasmsspa
dc.subject.keywordVaginal smearsspa
dc.subject.keywordWorld healthspa
dc.subject.keywordYoung adultspa
dc.titleImpact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Womenspa